Raymond James downgraded Editas Medicine ( EDIT, Financials) from outperform to market perform, citing extended development ...
Stifel analyst Dae Gon Ha lowered the firm’s price target on Editas Medicine (EDIT) to $11 from $17 and keeps a Buy rating on the shares.
Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback